News

In March, FDA approved biosimilar versions of established biologic drugs for autoimmune diseases and skeletal-related events, adalimumab biosimilars demonstrated sustained efficacy and acceptance among patients, and affirmed CT-P41’s potential as an alternative treatment options in clinical practice.

Less than 2 months after being the subject of an FDA AdComm meeting, Abbott's TriClip TEER System has received approval for tricuspid regurgitation.

The FDA approved iloperidone for acute treatment of bipolar I disorder on April 02, 2024, according to Vanda Pharmaceuticals.

The phase 2b trial showed a statistically significant improvement of BCVA at week 52 in both the high-dose and low-dose MCO-010 cohorts compared with sham.

Autism presents differently in males and females, which could explain why fewer females are diagnosed. Females are also often limited or excluded in autism research.

This meta-analysis demonstrates the possibilities for probiotic supplementation, though additional multi-center clinical studies with larger samples may be needed.

Cleveland Clinic lung transplant experts rejoin Lungcast to discuss optimization of the lung allocation system to continue reducing waitlist times and patient mortality.

Positive phase 2 results from NEPTUNE represent the best treatment failure rates observed among active studies in non-infectious uveitis.

Our March 2024 hepatology month in review highlights HCPLive’s coverage of the FDA approval of resmetirom for MASH/NASH and other key hepatic pipeline news.

A recap of the biggest FDA news and decisions in cardiovascular medicine from the first 3 months of 2024, with commentary on recent announcements by Deepak Bhatt, MD, MPH, MBA.

Verve Therapeutics announced plans to voluntary pause enrollment of the Heart-1 trial, citing an adverse event and consultation with DSMB, with plans to shift focus to VERVE-102 and Heart-2 trial.

In a systematic review and meta-analysis of available data, lotilaner ophthalmic solutions outperformed placebo, with few side effects, in treating Demodex blepharitis.

The application for generic roflumilast cream, 0.3%, for plaque psoriasis may end up entitling Padagis to 180 days of market exclusivity.

Topline results from AURORA indicate that while bitopertin significantly reduced PPIX levels, improvements in light tolerance were not statistically significant.

SZN-043 showed evidence of target engagement, Wnt signal activation, and effects on liver function, supporting its advancement to a phase 1b trial in severe alcohol-associated hepatitis.

This clinical quiz will test your knowledge on management of LDL-C special populations with nonstatin therapies based on the ACC's 2022 expert clinical decision pathway.

Findings highlight the negative impact of bowel urgency and bowel urgency-related accidents on the daily lives of patients with UC and CD.

In this review of the top stories in dermatology in March, several were highlighted such as the recent report on benzene in skincare products and the FDA’s approval of spesolimab for generalized pustular psoriasis.

This March 2024 psychiatry month in review highlights positive phase 2b and phase 2a data for drugs targeting treatment-resistant depression, generalized anxiety disorder, and PTSD.

New data show COPD and IPF, among other interstitial lung diseases, are more significantly associated with poor 30-day outcomes from COVID-19 than asthma.

Iron-deficient patients on an SGLT2 inhibitor at baseline experienced greater increases in hemoglobin levels with ferric derisomaltose compared with those not taking one.

This post-AAD interview with Chovatiya covered takeaways regarding recent data on upadacitinib for vitiligo, tapinarof for eczema, and lutikizumab for hidradenitis suppurativa.

In this episode, Alan Lotvin, MD, of Sequel Med Tech, joins hosts for a deep dive into the twiist automated insulin delivery system, which received clearance for people with T1D in March 2024.

Abusing psychoactive substances, such as ADHD medication, cannabis, and nicotine, not only creates an addiction but can impact mental distress.

In this episode, hosts discuss GLP-1 RA use and CGM technology, updates in once-weekly insulins, the concept of continuous ketone monitoring, and practical application of artificial intelligence into care.

In this interview segment, Del Rosso further explores the steps patients and clinicians should take in considering the recent Valisure report on benzene risk for skincare products with benzoyl peroxide.

A systematic review highlights the available evidence on the use of intravenous fluid in sickle cell vaso-occlusive crises and reported adverse outcomes.

FDA issued a warning for the the Impella left-sided blood pumps as it had received many reports of heart-wall tears, increasing the risk of death, hypertension, and more.